CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today announced it has selected Image Analysis Group ("IAG") as the image partner for its upcoming Berubicin clinical trials.
IAG’s Team published a new article ‘Artificial intelligence-based Clinical Decision Support systems using advanced medical imaging & Radiomics’, Elsevier’s Current Problems in Diagnostic Radiology, June 2020
ZiteLab Aps and IAG, Image Analysis Group Partner to Integrate IAG’s DYNAMIKA and the SAMRI Platforms to Advance Connectivity and Interoperability in Clinical Trials of Rheumatic Diseases
PIPE-505 is the first small molecule developed specifically for the treatment of sensorineural hearing loss (SNHL) associated with speech-in-noise impairment
Just published: Potential of Imaging and the role for AI in the management of COVID-19